

KOMBİNE TOPIKAL RETİNOİDLER

8. Bölüm

Algün POLAT EKİNCİ¹

ÖZET

Topikal retinoidlerin etkinliğini artırmak, lokal yan etkilerini azaltmak ve hastanın tek üründe birkaç farklı etki mekanizmalı molekülle tedavisini sağlamak amacıyla fiks kombinasyonları üretilmiştir. Bu bölümde akne tedavisinde kullanılan adapalen %0.1 ve benzoil peroksit %2.5, adapalen %0.3 ve benzoil peroksit %2.5, klindamisin fosfat %1.2 ve tretinoin %0.025 ile izotretinoin %0.05 ve eritromisin %2 kombinasyonlarının yanı sıra psoriasis tedavisinde kullanılan halobetazol propiyonat %0.01 ve tazaroten %0.045 kombinasyonu moleküler yapıları, etkinlik ve güvenlik verileri, endikasyonları ve kontrendikasyonları eşliğinde özetlenmiştir.

Giriş

Kombinasyon tedavileri etken moleküllerin farklı ve tamamlayıcı mekanizmalarını bir araya getirerek daha kullanışlı son ürünler oluşturmayı amaçlar. Özellikle multifaktöryel patogenezi olan akne vulgaris, psoriasis vulgaris gibi hastalıkların tedavisinde topikal retinoidlerin farklı ajanlarla fiks kombinasyonları bu amaçla üretilmiş ve kullanıma sunulmuştur (1). Bu bölümde kombine topikal retinoidler moleküler yapıları, etki mekanizmaları, endikasyonları, kontrendikasyonları, kullanım şekilleri ile etkinlik ve güvenlik verileri eşliğinde gözden geçirilmektedir. Bu kombinasyonların temel özellikleri Tablo 19'da özetlenmiştir.

¹ Doç. Dr. Algün POLAT EKİNCİ, İstanbul Üniversitesi Tıp Fakültesi Deri ve Zührevi Hastalıklar Bölümü algun.ekinci@istanbul.edu.tr

kombinasyonu uzun senelerdir ülkemizde akne tedavisinde kullanılmakla beraber bir çok ülkede daha etkili moleküllerin kullanıma girmesiyle önemini kaybetmiştir. Hafif orta şiddetli aknenin topikal tedavisinde kullanılabilir. Halobetazol propionat %0.01 ve tazaroten %0.045 kombinasyonu ile psoriasisın topikal tedavisinde etkili düzeyde iyilik elde edilmiştir. Ancak pahalı bir tedavi olması kullanımını kısıtlayıcı olabilir.

Kaynaklar

1. Keating GM. Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years. *Am J Clin Dermatol.* 2011;12(6):407-20.
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022320s004lbl.pdf
3. Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, et al; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. *Br J Dermatol.* 2009; 161(5):1180-9.
4. Dreno B, Tan J, Rivier M, Martel P, Bissonnette R. Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split-face randomized controlled trial. *J Eur Acad Dermatol Venereol.* 2017; 31(4):737-742.
5. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, et al; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. *J Am Acad Dermatol.* 2007; 57(5):791-9.
6. Gold LS, Tan J, Cruz-Santana A, Papp K, Poulin Y, Schlessinger J, et al; Adapalene-BPO Study Group. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. *Cutis.* 2009;84(2):110-6.
7. Tan J, Gollnick HP, Loesche C, Ma YM, Gold LS. Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients. *J Dermatolog Treat.* 2011;22(4):197-205.
8. Zouboulis CC, Fischer TC, Wohlrab J, Barnard J, Alió AB. Study of the efficacy, tolerability, and safety of 2 fixed-dose combination gels in the management of acne vulgaris. *Cutis.* 2009;84(4):223-9.
9. Gonzalez P, Vila R, Cirigliano M. The tolerability profile of clindamycin 1%/benzoyl peroxide 5% gel vs. adapalene 0.1%/benzoyl peroxide 2.5% gel for facial acne: results of a randomized, single-blind, split-face study. *J Cosmet Dermatol.* 2012;11(4):251-60.
10. Dréno B, Kaufmann R, Talarico S, Torres Lozada V, Rodríguez-Castellanos MA, et al. Combination therapy with adapalene-benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double-blind controlled study. *Br J Dermatol.* 2011;165(2):383-90.
11. Gold LS, Cruz A, Eichenfield L, Tan J, Jorizzo J, Kerrouche N, et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle-controlled,

- double-blind study of adapalene 0.1%-benzoyl peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. *Cutis*. 2010;85(2):94-104.
12. Pariser DM, Westmoreland P, Morris A, Gold MH, Liu Y, Graeber M. Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris. *J Drugs Dermatol*. 2007;6(9):899-905.
 13. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207917Orig1s000lbl.pdf
 14. Stein Gold L, Weiss J, Rueda MJ, Liu H, Tanghetti E. Moderate and Severe Inflammatory Acne Vulgaris Effectively Treated with Single-Agent Therapy by a New Fixed-Dose Combination Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel: A Randomized, Double-Blind, Parallel-Group, Controlled Study. *Am J Clin Dermatol*. 2016;17(3):293-303.
 15. Del Rosso JQ, Stein Gold L, Johnson SM, Rueda MJ, Baldwin H, Lain EL, et al. Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Oral Doxycycline in Subjects with Severe Inflammatory Acne Who Are Candidates for Oral Isotretinoin. *J Drugs Dermatol*. 2018;17(3):264-273.
 16. Dréno B, Bissonnette R, Gagné-Henley A, Barankin B, Lynde C, Chavda R, et al. Long-Term Effectiveness and Safety of Up to 48 Weeks' Treatment with Topical Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in the Prevention and Reduction of Atrophic Acne Scars in Moderate and Severe Facial Acne. *Am J Clin Dermatol*. 2019;20(5):725-732.
 17. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/050802lbl.pdf
 18. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/050802_ziana_toc.cfm
 19. Ochsendorf F. Clindamycin phosphate 1.2% / tretinoin 0.025%: a novel fixed-dose combination treatment for acne vulgaris. *J Eur Acad Dermatol Venereol*. 2015;29 Suppl 5:8-13.
 20. Dréno B, Bettoli V, Ochsendorf F, Layton AM, Perez M, Dakovic R, et al. Efficacy and safety of clindamycin phosphate 1.2%/tretinoin 0.025% formulation for the treatment of acne vulgaris: pooled analysis of data from three randomised, double-blind, parallel-group, phase III studies. *Eur J Dermatol*. 2014;24(2):201-9.
 21. Kircik LH, Peredo MI, Bucko AD, Loss RW Jr, Fowler JF Jr, Wortzman M, et al. Safety of a novel gel formulation of clindamycin phosphate 1.2%-tretinoin 0.025%: results from a 52-week open-label study. *Cutis*. 2008;82(5):358-66.
 22. Goreshi R, Samrao A, Eht BD. A double-blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. *J Drugs Dermatol*. 2012;11(12):1422-6.
 23. Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebo-controlled clinical trial to compare a gel containing a combination of Isotretinoin (0.05%) and erythromycin (2%) with gels containing Isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris. *Dermatology*. 1999;199(3):242-7.
 24. Marazzi P, Boorman GC, Donald AE, Davies HD. Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. *J Dermatolog Treat*. 2002;13(3):111-7.
 25. <https://kt.ilacprospektusu.com/ilac/11403-isotrexin-jel-kt>

26. Chen C, Jensen BK, Mistry G, Wyss R, Zultak M, Patel IH, et al. Negligible systemic absorption of topical İzotretinoin cream: implications for teratogenicity. *J Clin Pharmacol.* 1997;37(4):279-84.
27. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209354s000lbl.pdf.
28. Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. *J Am Acad Dermatol.* 2018;79(2):287-293.
29. Ramachandran V, Bertus B, Bashyam AM, Feldman SR. Treating Psoriasis with Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. *Ann Pharmacother.* 2020;54(9):872-878.